The Future Role of Anti-Tumour Necrosis Factor (TNF) Products in the Treatment of Rheumatoid Arthritis

ISSN： 0012-6667

Source： Drugs, Vol.55, Iss.5, 1998-05, pp. : 613-620

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Future Role of Anti-Tumour Necrosis Factor- Products in the Treatment of Crohn's Disease

By van Hogezand R.A. Verspaget H.W.

Drugs, Vol. 56, Iss. 3, 1998-09 ,pp. : 299-305

Adis International

Access to resources Recommend Favorite

Guidelines on the use of anti-tumour necrosis factor (TNF) therapies in patients with rheumatoid arthritis (RA) have been updated

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 475, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

According to The British Society for Rheumatology guidelines, 5.6% of outpatients with rheumatoid arthritis (RA) in the West Midlands, UK, are eligible for anti-tumour necrosis factor (TNF) monoclonal antibody therapy

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 422, 2003-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Anti-TNF Treatment in Rheumatoid Arthritis

Current Pharmaceutical Design, Vol. 17, Iss. 29, 2011-10 ,pp. : 3141-3151

Bentham Science Publishers

Access to resources Recommend Favorite

Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis: Pharmacokinetic Modelling Analysis of Interaction between a Soluble Target and a Drug

By Stepensky David

Clinical Pharmacokinetics, Vol. 51, Iss. 7, 2012-07 ,pp. : 443-455

Adis International

Access to resources Recommend Favorite